	US 12,076,383 B2
	Compositions and methods for inducing humoral and cellular immunities against tumors and cancer
Lynda Sutton, Durham, NC (US); Jill P. Smith, Camp Hill, PA (US); Nicholas Osborne, Durham, NC (US); Brian E. Huber, Durham, NC (US); and Allen Cato, Durham, NC (US)
Assigned to Cancer Advances Inc., Durham, NC (US)
Filed by Cancer Advances Inc., Durham, NC (US)
Filed on Nov. 18, 2022, as Appl. No. 18/056,843.
Application 18/056,843 is a division of application No. 16/622,841, granted, now 11,583,576, previously published as PCT/US2018/037737, filed on Jun. 15, 2018.
Claims priority of provisional application 62/520,267, filed on Jun. 15, 2017.
Prior Publication US 2023/0086898 A1, Mar. 23, 2023
Int. Cl. A61K 39/00 (2006.01); A61K 39/39 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01)

CPC A61K 39/001102 (2018.08) [A61K 39/39 (2013.01); A61K 39/39541 (2013.01); A61P 35/00 (2018.01); C07K 16/2869 (2013.01); A61K 2039/505 (2013.01); A61K 2039/575 (2013.01); A61K 2039/6037 (2013.01); A61K 2039/627 (2013.01); A61K 2039/852 (2018.08)]

9 Claims

1. A method for preventing, reducing, and/or eliminating formation of fibrosis associated with a pancreatic tumor and/or a cancer, the method comprising contacting the pancreatic tumor and/or the cancer with a first composition comprising a gastrin peptide conjugated to an immunogenic carrier via a linker and a second composition comprising an immune checkpoint inhibitor, wherein the gastrin peptide comprises an amino acid sequence selected from the group consisting of EGPWLEEEEE (SEQ ID NO: 1), EGPWLEEEE (SEQ ID NO: 2), EGPWLEEEEEAY (SEQ ID NO: 3), and EGPWLEEEEEAYGWMDF (SEQ ID NO: 4) and the checkpoint inhibitor inhibits a biological activity of a target polypeptide selected from the group consisting of cytotoxic T-lymphocyte antigen 4 (CTLA4), programmed cell death-1 receptor (PD-1), and programmed cell death 1 receptor ligand (PD-L1).